Correction: First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: study protocol for a prospective, multicenter, phase II study

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-03-02
DOI
https://doi.org/10.3389/fonc.2026.1726750
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: study protocol for a prospective, multicenter, phase II study

Qing Ma, Xiaofen Li, D. Cao, Hao Li et al.
Frontiers in Oncology
Neuroendocrine Tumor Research Advances
article

Correction: First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: study protocol for a prospective, multicenter, phase II study

Qing Ma, Xiaofen Li, D. Cao, Hao Li, Chen Chang
article en

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 16
Sichuan University (CN), West China Medical Center of Sichuan University (CN), West China Hospital of Sichuan University (CN)
Quality Education
Openalex Percentile: Top 38%
Neuroendocrine Tumor Research Advances
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.